Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose vs Standard Chemotherapy in High-Risk Breast Cancer (IBCSG 15-95)
NCT00002784Phase 3Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Jun 1996
- Primary completion
- Aug 2011
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of epirubicin and cyclophosphamide in breast cancer (2 arms), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Disease-Free Survival at 16 years. Started Jun 1996; status: completed.
02
Drugs
epirubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00002784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002784.